The latest price target for Prelude Therapeutics (NASDAQ:PRLD) was reported by JMP Securities on December 11, 2024. The analyst firm set a price target for $4.00 expecting PRLD to rise to within 12 months (a possible 212.65% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Prelude Therapeutics (NASDAQ:PRLD) was provided by JMP Securities, and Prelude Therapeutics reiterated their market outperform rating.

The last upgrade for Prelude Therapeutics Inc happened on September 19, 2024 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for Prelude Therapeutics Inc.

The last downgrade for Prelude Therapeutics Inc happened on February 20, 2024 when HC Wainwright & Co. changed their price target from N/A to $5 for Prelude Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on December 11, 2024 so you should expect the next rating to be made available sometime around December 11, 2025.

While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a reiterated with a price target of $7.00 to $4.00. The current price Prelude Therapeutics (PRLD) is trading at is $1.28, which is out of the analyst’s predicted range.